Wells Fargo raised the firm’s price target on Ventyx Biosciences to $7 from $3 and keeps an Equal Weight rating on the shares. In its outlook, the firm thought in 2024 Ventyx would re-focus the co around its NLRP3 assets and given the preclinical weight loss data from a competitor for this moa, this is quite certain. Wells awaits additional data on March 11 before getting more constructive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences reports Q4 EPS (79c), consensus (90c)
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
- ZyVersa data adds evidence of NLRP3 focus in obesity, says Piper Sandler
- NLRP3 data could drive renewed focus on Ventyx candidates, says Jefferies
- Ventyx jump attributable to competitor data, says Oppenheimer
